Elbrit Life Sciences dreaming Big on Indian Pharmaceutical Business
‘Elbrit Life Sciences’, a new pharmaceutical company based in Mumbai, India, today opened gates for business in India. The company would be serving the South Indian states initially and aims to cover the entire country with time. According to the sources, the company would be targeting cardiac and diabetes product segments in the present year. Elbrit Life Sciences is a part of a global business group based in UK with investments in science, research and education. The group has significantly invested in next generation healthcare such as genetic therapy, molecular biology, DNA mapping and biomarkers. The group also owns world renowned scientific and academic publishing brands.

World Health Organization (WHO) has issued its first guidance for the treatment of hepatitis C which affects an estimated 130 million to 150 million people and results in 3,50,000 to 5,00,000 deaths a year.
The scientists, from Oxford Health NHS, confirmed that some patients with severe depression who have not responded to other treatments, can be treated with ketamine which has a rapid antidepressant effect. Ketamine is a licensed medical drug and is very widely used as an anaesthetic and in pain relief. It is also used as a recreational drug or drug of abuse, and is to be reclassified as a Class B banned substance.
The U.S. Food and Drug Administration approved Otezla (apremilast), manufactured for Celgene Corporation, Summit, N.J., to treat adults with active psoriatic arthritis (PsA), which is a form of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with PsA. Joint pain, stiffness and swelling are the main signs and symptoms of PsA.
Formation of plaques is more frequent in coronary arteries of HIV positive men than HIV negative men, according to a new study by National Institutes of Health grantees. The research describes that HIV-infected men are at higher risk for a heart attack than their HIV-uninfected which is published in Annals of Internal Medicine.
Fixed Dose Combinations (FDCs) manufacturers are invited to present their proposal for approval of the safety and efficacy of permitted for manufacture for sale in the country without due approval from office of Drug Controller General of India (DCGI).
On thursday, 27th march 2014, the World Health Organisation (WHO) presented official certification to India for its ‘Polio Free’ status. India is among other countries in its South East Asian region which have been certified as being free of the wild polio virus. Ghulam Nabi Azad, health minister of India, received the official certificate from WHO.

